Insider Buying at Atrium Therapeutics Signals Strong Confidence in RNA‑Based Growth
Insider buys at Atrium Therapeutics signal confidence in its RNA‑based pipeline and strategic alignment, showing potential upside as Phase II trials and regulatory milestones loom.
5 minutes to read